

## DEVELOPMENT OF THERAPEUTIC AREA-SPECIFIC DATA STANDARDS FOR BRAIN DISEASES

Jon Neville, Critical Path Institute, Tucson AZ





### Contributors




Jon Neville<sup>1</sup>, Steve Kopko<sup>2</sup>, Bess LeRoy<sup>1</sup>, Mark Forrest Gordon<sup>3</sup>, Susan De Santi<sup>4</sup>, Andreas Jeromin<sup>5</sup>, Ellen Mowry<sup>6</sup>, Mark Austin<sup>7</sup>, Patricia Cole<sup>8</sup>, Ken Marek<sup>9</sup>, Jerry Novak<sup>10</sup>, Klaus Romero<sup>1</sup>, Bob Stafford<sup>1</sup>, Emily Hartley<sup>1</sup>, Amy Palmer<sup>2</sup>, Rhonda Facile<sup>2</sup>, Kewei Chen<sup>11</sup>, Adam Fleisher<sup>11</sup>, Joanne Odenkirchen<sup>12</sup>, Enrique Avilés<sup>1</sup>, Fred Lublin<sup>13</sup>, Eric Reiman<sup>11</sup>, Geoffrey Manley<sup>14</sup>, Lynn Hudson<sup>1</sup>, Diane Stephenson<sup>1</sup>

#### **AFFILIATIONS:**

- 1 Critical Path Institute, Tucson, AZ
- 2 Clinical Data Interchange Standards Consortium, Austin, TX
- 3 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
- 4 Piramal Pharma Inc, Boston, MA
- 5 Quanterix, Lexington, MA
- 6 Johns Hopkins University School of Medicine, Baltimore, MD
- 7 Ixico, London, UK
- 8 Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL
- 9 Institute for Neurodegenerative Disorders, New Haven, CT
- 10 J&J PRD, Titusville, NJ
- 11 Banner Alzheimer's Institute, Phoenix, AZ
- 12 National Institute for Neurological Disorders and Stroke
- 13 Mount Sinai Medical Center, New York, NY
- 14 University of California, San Francisco, San Francisco, CA

## Why do drug development programs fail?





**Reason by phase** 

FDA Data, 2010

#### **Perspective for Brain Disorders**



- Failure rate of new therapies is exceedingly high for brain disorders
- Placebo effect is a challenge
- Outcome measures and variability
- Biomarkers are in urgent need



## FDA's Critical Path Initiative





Memorandum of Understanding created between the FDA and C-Path in 2005

#### **Critical Path Institute Consortia**



#### **Eight global consortia collaborating with 1,300+ scientists and 61 companies**

CRITICAL PATH INSTITUTE	<b>Coalition Against Major Diseases</b> Focusing on diseases of the brain	
	Critical Path to TB Drug Regimens Testing tuberculosis drug combinations	<ul> <li>Biomarkers</li> <li>Clinical Outcome Assessment Instruments</li> <li>Clinical Trial Simulation Tools</li> <li>Data Standards</li> <li>In Vitro Tools</li> </ul>
CRITICAL PATH INSTITUTE National Multiple Sclerosis Society	Multiple Sclerosis Outcome Assessments Consortium Measuring drug effectiveness in MS	
	Polycystic Kidney Disease Consortium New imaging biomarkers	
	Patient-Reported Outcome Consortium Measuring drug effectiveness Electronic Patient-Reported Outcome Consortium Electronic capture of drug effectiveness	
	Predictive Safety Testing Consortium Drug safety	
<b>CFAST</b>	Coalition For Accelerating Standards and Therapies Data standards	

## Clinical Data Interchange Standards Consortium (CDISC)

- Global, open, multi-disciplinary, vendor-neutral non-profit standards developing organization (SDO)
  - Founded in 1997; incorporated in 2000
  - > 300 organizational members
  - (academia, biopharma, service and technology providers, etc)
  - Works closely with other standards organizations (ISO, ANSI, HL7)
  - Standards downloaded in over 90 countries

Established global industry standards to support the electronic acquisition, exchange, submission and archiving of data to streamline biomedical research (open via www.cdisc.org)









# **CDISC** specifies how to structure the data you have collected in a database, not what *should* be collected nor how to conduct clinical assessments or protocols



#### **Starting Point** Study Number Nine member companies agreed to share data from 24 trials; 6500 subjects **Disparate Legacy Data** The data were not in a common format The data needed to be combined in a consistent manner **CDISC Data Standards** Visit Number MMSE V ADAS-COP All data were remapped to the CDISC AD standard Study Number Visit Number VMMSE ADAS-cog Study Number v Visit Number v MMSE v ADAS-cos Results Integrated Data A new in clinical trial simulation tool was created; endorsed by FDA & EMA

First ever therapeutic-area CDISC user guide published

9


## Alzheimer's disease CDISC standard




Concepts covered by the Alzheimer's CDISC User Guide	ADNI Alzheimer's Disease Neuroimaging Initiativ
ApoE Genotype Family History of AD Volumetric MRI PET, PET/CT (FDG, Florbetapir, PiB) CSF Biomarkers and Sampling	
Outcome Assessment Scales ADAS-COG CDR	Therapeutic Area Data Standards User Guide for Alzheimer's Disease and Mild Cognitive Impairment Version 2.0 Prepared by the CFAST Alzheimer's Development Team
AVLT FAQ Modified Hachinski	
DAD ADCS-ADL MCI NPI	
CGI GDS	www.cdisc.org/therapeutic

## Data standards strive to elucidate the whole story









Download PD CDE Recommendations 🗐

What's covered in the CDISC Parkinson's Disease Data Standard?



SDTM PD Therapeutic Area Supplement (new)

- UPDRS/ MDS-UPDRS
- Imaging: MRI, PET/SPECT
- Deep Brain Stimulation
- Neuropathology
- Family History of PD



www.cdisc.org/therapeutic



- 23 outcome assessment scales
- Disease course and characteristics
- Relapse
- OCT (Retinal Nerve Fiber Layer Thickness)
- Visually Evoked Potential (VEP)
- Visual acuity

V2.0 in process; will include imaging



National Multiple Sclerosis Society



www.cdisc.org/therapeutic

## Traumatic Brain Injury Draft User Guide Content



- Glasgow Outcome Scale Extended (GOS-E)
- Rey Auditory Verbal Learning Test (RAVLT)
- Glasgow Coma Scale (GCS)
- Disability Rating Scale (DRS)
- Expanded Disability Rating Scale -Postacute Interview (E-DRS-PI)
- Rand-36 (public domain version of the SF-36)
- Rivermead Postconcussive Symptom Questionnaire (RPQ)
- Trail Making Test (TMT)

>35 instruments in total are in process, some pending copyright approval

- TBI history
- Imaging
- Pupil measurements and reactivity
- Second insults and complications

The TBI User Guide will be available for public comment in June!





#### www.cdisc.org/therapeutic

## The Big Picture....FDA will require data standards



U.S. Department of Health and Human Services

Drugs

Food



Home

#### U.S. Food and Drug Administration

Protecting and Promoting Your Health

Medical Devices Radiation-Emitting Products Vaccines, Bloo

#### Drugs

Home > Drugs > Development & Approval Process (Drugs) > Forms & Submission Requirements

#### Development & Approval Process (Drugs)

Forms & Submission Requirements

Electronic Submissions to CDER

CDER Data Standards Program

Electronic Common Technical Document (eCTD)

Electronic Regulatory Submissions and Review Helpful Links

Electronic Submissions Presentations

#### **Study Data Standards**

CDER strongly encourages IND sponsors and ND standards for the submission of applications. Such development lifecycle, so that data standards are These resources are intended to assist submitters CDER.

CDER's Study Data requirements are covered in t Conformance Guide that are available on the Stud

#### Study Data Technical Conforma

This Guide provides technical specifications, recor standardized electronic study data.

#### **Data Standards Catalog**

Providing Regulatory Submissions In Electronic Format — Standardized Study Data

#### Guidance for Industry

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER)

### CAMD AD CSF Letter of Support



DEPARTMENT OF HEALTH & HUMAN SERVI

PUBLIC HEALTH SERVICE

Food and Drug Administration Center for Drug Evaluation and Research 10903 New Hampshire Avenue Silver Spring, MD 20993

Date: February 26, 2015

We encourage the inclusion of these exploratory CSF biomarkers in clinical trials to evaluate their clinical utility for identifying patients likely to show clinical progression of their MCI symptoms for the purpose of clinical trial enrichment. We consider data collection on this biomarker to be exploratory in nature. When including these biomarkers in clinical trials, sponsors are encouraged to employ consensus AD CDISC<sup>2</sup> standards for data harmonization. We believe that sharing and integrating data across trials can foster an accelerated path for AD drug development programs. If sponsors intend to include analyses of these biomarkers to support regulatory decision making for a given IND drug development program, they should prospectively discuss with the Division of Neurology Products in CDER.

Janet Woodcock, M.D.

Director, CDER

U.S. Food and Drug Administration

http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm434382.htm

## **Standards Directory**

